Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.37 +0.9%	$1.81	$1.11 ▼ $5.00	$630.76M	1.81	1.58 million shs	451,120 shs
DBVT DBV Technologies	$11.54 +12.0%	$9.42	$2.20 ▼ $12.78	$317.72M	-0.59	191,181 shs	29,062 shs
ITOS iTeos Therapeutics	$10.17 +0.1%	$8.98	$4.80 ▼ $18.13	$389.63M	1.49	692,274 shs	386,108 shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	+2.60%	+13.40%	+78.20%	-32.09%
DBVT DBV Technologies	0.00%	+25.63%	+41.76%	+77.52%	+203.66%
ITOS iTeos Therapeutics	0.00%	+2.21%	-0.29%	+88.68%	-31.19%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.5531 of 5 stars	3.5	1.0	0.0	0.0	1.8	3.3	0.6
DBVT DBV Technologies	3.8832 of 5 stars	4.4	3.0	0.0	0.0	3.2	2.5	0.6
ITOS iTeos Therapeutics	3.2084 of 5 stars	4.1	2.0	0.0	0.0	1.4	3.3	0.6
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	293.25% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	27.83% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	55.92% Upside
NTGN Neon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NTGN, AUTL, ITOS, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	62.33	N/A	N/A	$1.61 per share	1.47
DBVT DBV Technologies	$4.15M	76.16	N/A	N/A	$1.42 per share	8.13
ITOS iTeos Therapeutics	$35M	11.12	N/A	N/A	$16.16 per share	0.63
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A

Latest NTGN, AUTL, ITOS, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
DBVT DBV Technologies	N/A	0.72	0.72
ITOS iTeos Therapeutics	N/A	14.13	14.13
NTGN Neon Therapeutics	0.43	1.58	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
DBVT DBV Technologies	71.74%
ITOS iTeos Therapeutics	97.16%
NTGN Neon Therapeutics	54.71%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
DBVT DBV Technologies	1.44%
ITOS iTeos Therapeutics	12.50%
NTGN Neon Therapeutics	38.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable

NTGN, AUTL, ITOS, and DBVT Headlines

Recent News About These Companies

Neon Therapeutics Inc (NTGN_old) Stock Forums - Investing.com

June 29, 2025 | investing.com

Neon Gold Records, Avenue A unite to launch Futures Music Group

October 24, 2024 | musicbusinessworldwide.comM

BioNTech grows in cell therapies, buying Kite's TCR platform

September 1, 2024 | pharmaphorum.comP

Neon Trap Defense

April 13, 2024 | kotaku.comK

BCYC Bicycle Therapeutics plc

April 9, 2024 | seekingalpha.com

neon oscillator

March 20, 2024 | hackaday.comH

NTGN_old Historical Data

February 20, 2024 | investing.com

2000 Plymouth Neon

January 13, 2024 | cars.comC

NBCO Neon Bloom, Inc.

December 22, 2023 | seekingalpha.com

Kansas City Ferris wheel could be out-dazzled by what will soon lie below: Neon Alley

November 13, 2023 | kansascity.comK

Starfield Neon shops and locations – every vendor in Neon

November 4, 2023 | videogamer.comV

A Nixie Clock With Neon Bulb Logic

October 5, 2023 | hackaday.comH

Starfield | Where To Get Neon (Ne)

September 29, 2023 | hardcoregamer.comH

Starfield Neon City guide – everything you need to know

September 14, 2023 | videogamer.comV

Starfield: All Shops in Neon City

September 10, 2023 | twinfinite.netT

Shadows in Neon

September 8, 2023 | ign.comI

Starfield Neon city guide

August 19, 2023 | pcgamesn.comP

Apex Legends Neon Network Collection Event

August 4, 2023 | ign.comI

Fab Five: Neon fashion finds to brighten up your summer wardrobe

July 31, 2023 | vancouversun.comV

Neon White physical edition for PS5, Switch launches September 15

July 21, 2023 | gematsu.comG

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTGN, AUTL, ITOS, and DBVT Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.37 +0.02 (+0.85%)

Closing price 07/3/2025 03:53 PM Eastern

Extended Trading

$2.37 0.00 (0.00%)

As of 07/3/2025 04:02 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

DBV Technologies NASDAQ:DBVT

$11.54 +1.24 (+12.03%)

Closing price 07/3/2025 01:03 PM Eastern

Extended Trading

$11.59 +0.05 (+0.43%)

As of 07/3/2025 04:01 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

iTeos Therapeutics NASDAQ:ITOS

$10.17 +0.01 (+0.10%)

As of 07/3/2025 03:11 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Neon Therapeutics NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time